Nevertheless, the use of trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of HER-2, in combination with chemotherapy has markedly enhanced the survival of HER-2 positive patients with BC (Slamon et al., 2001; Perez et al., 2014). This evidence concerns the gene ERBB2 and breast cancer.